Editorial Perspectives On Cell Line Development

31. What's Behind BridgeBio's 30+ Drug Candidates? 7/15/2021

    Chief Business Officer Michael Henderson, M.D. opens up on the innerworkings of academic partnerships that are driving an unusually high pipeline of therapeutic candidates across a broad range of modalities in the rare genetic pediatric disease space.

32. GMP CAR T Manufacturing: The Poseida Approach 6/7/2021

    Promising clinical momentum and a recent IPO are fueling Poseida Therapeutics’ unique approach to manufacturing safe, accessible, and affordable allogeneic CAR T-cell therapies. CEO Eric Ostertag, M.D., Ph.D., shares the company’s differentiating factors.

33. The Placental Stem Cell Advantage 5/11/2021

    As Celularity makes its most significant clinical progress to date, the company is putting theories born of 20 years of postpartum placental stem cell research into practice. Could the production platform it’s building be the key to accessible, affordable allogeneic cell therapy?

34. Inside San Jose's Uncommon Biotech Accelerator 4/21/2021

    San Jose BioCube takes a unique approach to the incubator/accelerator model, capitalizing on big demand for the space that emerging-to-midsize biotechs need to grow their businesses. As a result, the accelerator is growing, too. Learn more about what to look for in accelerator space, whether or not you're in the Bay area.

35. Biologics Clinical Research: The Year's Best 4/16/2021

    Harry Selker, M.D. sits down with BioProcess Online for a candid discussion on the Clinical Research Forum’s work, its awards program that recognizes the year's best advances in clinical and translational research, and why that’s such an important structural element in the bridge between academia and industry. 

36. Can GDF11 Address Aging, One Disease At A Time? 3/24/2021

    Led by Dr. Mark Allen and backed by heavyweights like Peter Diamandis, M.D. and Tony Robbins, biopharma startup Elevian is charting the CMC and regulatory path for Growth Differentiation Factor 11 to make a therapeutic play in a host of age-related diseases.

37. Reshaping The Vaccine Manufacturing Paradigm 3/22/2021

    Uvax Bio’s unconventional approach brings a heretofore ignored physical component to vaccine design. Co-founders Dr. Ji Li and Jiang Zhu share why they think their platform is poised to revolutionize vaccine development, manufacturing, and distribution.

38. A Differentiated Approach To Allogeneic Cell Therapy Manufacturing 3/3/2021

    Celyad Oncology CEO Filippo Petti digs in on differentiating his company’s approach to developing and manufacturing allogeneic cell therapies for several oncology indications, including the company's technology platform and scale-up strategies in Celyad’s Belgium-based clinical manufacturing facility.  

39. Genetically Engineering An IL-15 Superagonist 9/25/2020

    SOTIO’s genetically-engineered SO-C101 is showing promise as a monotherapy and combined with immunotherapies in pre-clinical tests and also recently in a phase I study. CBO Jens Hennecke, Ph.D. shared an update on the company’s Phase 1 progress and gave us a look behind the curtains at the work it took to get to the clinic.